Neurocrine Biosciences (NBIX) Retained Earnings (2010 - 2026)

Neurocrine Biosciences has reported Retained Earnings for 17 years, with the latest figure at $589.6 million in Q1 2026.

• For the quarter ending Q1 2026, Retained Earnings rose 6451.11% year-over-year to $589.6 million; the trailing twelve-month figure through Mar 2026 stood at $589.6 million (up 6451.11% YoY), and the FY2025 full-year result was $13.1 million, down 55.14% from the prior year.
• Retained Earnings for Q1 2026 stood at $589.6 million, up from $13.1 million in the prior quarter.
• The five-year high for Retained Earnings was $589.6 million in Q1 2026, with the low at -$564.3 million in Q2 2022.
• Historically, Retained Earnings has averaged -$75.0 million across 5 years, with a median of $3.3 million in 2024.
• Annual changes were most pronounced in 2022 — Retained Earnings plunged 124050.0% — and 2026, when it soared 6451.11%.
• Neurocrine Biosciences' Retained Earnings stood at -$406.8 million in 2022, then soared by 101.72% to $7.0 million in 2023, then jumped by 317.14% to $29.2 million in 2024, then tumbled by 55.14% to $13.1 million in 2025, then surged by 4400.76% to $589.6 million in 2026.
• The last three Retained Earnings figures came in at $589.6 million (Q1 2026), $13.1 million (Q4 2025), and $294.0 million (Q3 2025), per Business Quant data.